Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLR869
- Development stage
- Preclinical
- Lead developer
- Alaunos Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
VLR869 is a preclinical bispecific antibody candidate being developed for the treatment of pulmonary arterial hypertension (PAH), secondary pulmonary hypertension (PH), and other cardiopulmonary diseases. Originally developed by Velaris Therapeutics, which was acquired by Alaunos Therapeutics in October 2026, VLR869 is designed to target undisclosed pathways involved in pulmonary vascular remodeling and disease progression. The candidate is currently in the discovery stage and is intended to serve as a foundation for high-impact combination therapies.
Beyond the preview
Go deeper on VLR869.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLR869.